Artera Receives $90 Million Investment

Artera developed a cancer screening test using artificial intelligence technology. They received a $90 million investment for this test. Artera received a $90 million investment from a group of investors including Marc Benioff. Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital and The Factory also participated in this investment round.

Also See: Bard, Google’s AI App to Rival ChatGPT, Access Granted

Artera

Artera's new $90 million investment brings the company's total investment to date to $135 million. The investment will be used for R&D and distribution of the company's test in the US and international markets. Artera is a cancer screening test and personalized care company. It has a particular focus on prostate cancer. Founded in 2015 by Andre Esteva under the name Well Health, the company changed its name to Artera in September 2021. The company is headquartered in California.

Artera provides predictive data on the course of the disease to determine a person's chances of recovery. The company also provides data for personalized treatment plans, focusing on early diagnosis of the disease. This helps patients determine which treatments are right for them. Personalized cancer treatment is the application of therapies that are tailored to the genetic characteristics of the individual and the tumor.

These treatments provide a long-term treatment process by keeping cancerous cells under control. This helps patients live a more comfortable life and prolongs their life expectancy. Prostate cancer is one of the most common cancers in men and is the second leading cause of cancer-related deaths. Clinical studies show that a 50-year-old man has a 40% risk of developing prostate cancer. The American Cancer Society estimates that in 2023 there will be more than 288,000 new cases of prostate cancer and more than 34,000 men will die from the disease.